No Data
No Data
JMP Securities Maintains DBV Technologies(DBVT.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed for DBV Technologies on Strong VITESSE Trial Progress and FDA Collaboration
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading